While an FDA decision on its osteoporosis drug Evenity looms, Amgen isn't biding its time with its fellow bone drug Xgeva. The treatment for cancer-related bone problems just got a new ad campaign that includes a first-ever TV spot—and adds to an industrywide surge in oncology advertising.
